Patents by Inventor Robert Pejchal

Robert Pejchal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High affinity anti-CD3 antibodies, and methods for their generation and use
    Patent number: 12552863
    Abstract: Antibodies and antigen-binding fragments thereof with high affinity for CD3 and desirable developability profiles are provided, as well as methods for their manufacture and use.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: February 17, 2026
    Assignee: ADIMAB, LLC
    Inventors: Robert Pejchal, Caitlin Stein, Julia McCreary
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20250297016
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 9, 2025
    Publication date: September 25, 2025
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
  • Anti-Sortilin antibodies and methods of use thereof
    Patent number: 12358991
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: July 15, 2025
    Assignee: Alector LLC
    Inventors: Tina Schwabe, Michael Kurnellas, Arnon Rosenthal, Robert Pejchal, Anthony B. Cooper
  • VARIANT CH3 DOMAINS ENGINEERED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME, AND METHODS OF MAKING THEREOF
    Publication number: 20250223379
    Abstract: Variant CH3 domain polypeptides are provided that preferentially form CH3-CH3 heterodimers over CH3-CH3 homodimers. Such variant CH3 domains can be used to promote desired Fc pairing, thus providing for efficient development of bispecific and multispecific antibodies as well as Fc fusions of different formats. Methods of producing bispecific antibodies using such variant CH3 domains and for producing libraries containing such variant CH3 domains are also provided.
    Type: Application
    Filed: January 11, 2022
    Publication date: July 10, 2025
    Inventors: Caitlin STEIN, Robert PEJCHAL, Julia MCCREARY, Kyle BARLOW, Arvind SIVASUBRAMANIAN, Michael Benjamin BATTLES
  • VARIANT CH3 DOMAINS ENGINEERED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME, AND METHODS OF MAKING THEREOF
    Publication number: 20250215082
    Abstract: Variant CH3 domain polypeptides are provided that preferentially form CH3-CH3 heterodimers over CH3-CH3 homodimers. Such variant CH3 domains can be used to promote desired Fc pairing, thus providing for efficient development of bispecific and multispecific antibodies as well as Fc fusions of different formats. Methods of producing bispecific antibodies using such variant CH3 domains and for producing libraries containing such variant CH3 domains are also provided.
    Type: Application
    Filed: January 11, 2023
    Publication date: July 3, 2025
    Inventors: Caitlin STEIN, Robert PEJCHAL, Julia MCCREARY, Kyle BARLOW, Arvind SIVASUBRAMANIAN, Michael Benjamin BATTLES, Beth H. SHARKEY
  • Anti-sortilin antibodies and methods of use thereof
    Patent number: 12297277
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: May 13, 2025
    Assignee: Alector LLC
    Inventors: Tina Schwabe, Michael Kurnellas, Arnon Rosenthal, Robert Pejchal, Anthony B. Cooper
  • METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
    Publication number: 20250092144
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: November 22, 2024
    Publication date: March 20, 2025
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
  • ANTI-CCR8 AGENTS
    Publication number: 20250019449
    Abstract: The present invention provides, among other things, methods and compositions for diagnosing and/or treating cancer by targeting CCR8. In particular, the present invention provides technologies for depleting Treg cells, and particularly tumor-infiltrating Treg cells.
    Type: Application
    Filed: March 5, 2021
    Publication date: January 16, 2025
    Inventors: Alexander Y. Rudensky, George Plitas, Laura M. Walker, Noel Pauli, Robert Pejchal, Cory Ahonen
  • METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
    Publication number: 20240309097
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: April 14, 2022
    Publication date: September 19, 2024
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony COOPER
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230312712
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: February 24, 2023
    Publication date: October 5, 2023
    Applicant: Alectro LLC
    Inventors: Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
  • ANTI-CD3-BINDING DOMAINS AND ANTIBODIES COMPRISING THEM, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20230151097
    Abstract: Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.
    Type: Application
    Filed: November 11, 2022
    Publication date: May 18, 2023
    Inventors: Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
  • Anti-TREM2 antibodies and methods of use thereof
    Patent number: 11634489
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: April 25, 2023
    Assignee: Alector LLC
    Inventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230047941
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 9, 2022
    Publication date: February 16, 2023
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
  • HIGH AFFINITY ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20230002487
    Abstract: Antibodies and antigen-binding fragments thereof with high affinity for CD3 and desirable developability profiles are provided, as well as methods for their manufacture and use.
    Type: Application
    Filed: June 8, 2020
    Publication date: January 5, 2023
    Inventors: Robert PEJCHAL, Caitlin STEIN, Julia McCREARY
  • Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
    Patent number: 11542330
    Abstract: Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: January 3, 2023
    Assignee: Adimab, LLC
    Inventors: Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
  • FC VARIANTS WITH REDUCED EFFECTOR FUNCTION
    Publication number: 20220396622
    Abstract: The present invention provides Fc variants and polypeptides, e.g., antibodies and Fc fusion proteins, comprising such Fc variants. In particular, Fc variants with diminished effector function as a consequence of hinge region and CH2 domain mutations, e.g., LALE-PG, are provided. Such variants maintain antigen-binding and favorable developability profiles and may display improved expressability.
    Type: Application
    Filed: June 24, 2022
    Publication date: December 15, 2022
    Inventors: Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Michael Brown, Anthony Cooper
  • ENGINEERED PH-DEPENDENT ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20220380463
    Abstract: Engineered pH-dependent anti-CD3 binding domains and antibodies and/or antigen-binding domains comprising same, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 1, 2022
    Inventors: James GEOGHEGAN, Bianka PRINZ, Robert PEJCHAL
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220348656
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 9, 2022
    Publication date: November 3, 2022
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
  • METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
    Publication number: 20220251219
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: April 14, 2022
    Publication date: August 11, 2022
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
  • Anti-Sortilin antibodies and methods of use thereof
    Patent number: 11396546
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: July 26, 2022
    Assignee: Alector LLC
    Inventors: Tina Schwabe, Michael Kurnellas, Arnon Rosenthal, Robert Pejchal, Anthony B. Cooper